Tobira Therapeutics Doses First Patient in CENTAUR, A Phase 2b Study of Cenicriviroc in Patients with Non-Alcoholic Steatohepatitis
October 13, 2014Tobira Therapeutics dosed the first patient in its Phase 2b CENTAUR study to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis patients with cenicriviroc (CVC), following completion of a Phase 1 safety study in patients with liver cirrhosis.
More »
Regado Biosciences Appoints Michael A. Metzger CEO
October 10, 2014Regado Biosciences, Inc. appoints Michael A. Metzger, current president of Regado, to the additional post of chief executive officer and member of the board.
More »
Durata Therapeutics Presents New Data for DALVANCE™ at IDWeek 2014™
October 10, 2014Durata Therapeutics presents data in five posters at IDWeek 2014, providing insight into the activity of dalbavancin relative to vancomycin in treating ABSSSI and supporting further study in patients with osteomyelitis and prosthetic joint infections.
More »